Small molecule · developed by Recursion Pharmaceuticals
REC-994 is a drug studied in cerebral cavernous malformation, a disease of abnormal blood vessel clusters in the central nervous system.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05085561 | Phase 2 | Cerebral Cavernous Malformation | Completed | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cerebral Cavernous Malformation
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →